Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Gross Margin (2016 - 2026)

Cumberland Pharmaceuticals' Gross Margin history spans 16 years, with the latest figure at 7.26% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 1169.0% to 7.26% in Q4 2025 year-over-year; TTM through Dec 2025 was 57.1%, a 206.0% increase, with the full-year FY2025 number at 57.1%, up 206.0% from a year prior.
  • Gross Margin hit 7.26% in Q4 2025 for Cumberland Pharmaceuticals, down from 88.08% in the prior quarter.
  • Over the last five years, Gross Margin for CPIX hit a ceiling of 145.63% in Q4 2022 and a floor of 18.95% in Q4 2024.
  • Historically, Gross Margin has averaged 67.62% across 5 years, with a median of 80.36% in 2022.
  • Biggest five-year swings in Gross Margin: soared 8536bps in 2022 and later crashed -10260bps in 2024.
  • Tracing CPIX's Gross Margin over 5 years: stood at 60.26% in 2021, then soared by 142bps to 145.63% in 2022, then plummeted by -43bps to 83.64% in 2023, then crashed by -123bps to 18.95% in 2024, then surged by 62bps to 7.26% in 2025.
  • Business Quant data shows Gross Margin for CPIX at 7.26% in Q4 2025, 88.08% in Q3 2025, and 81.44% in Q2 2025.